FERTILLIGEN

Fertilligen develops a novel treatment for male infertility. Using Tet3 proteins, purified and injected concurrently with infertile spermatids, Fertillegen has been able to create successful blastocysts in vitro. Roughly 10% of males experience fertility issues. Of these, about 45% have no available treatment options. In the U.S., approximately 3.2 million men have no recourse for their fertility issues. Fertiligen’s project could address the needs of this population and open up previously closed parts of this market. As of 2020, the company was working to demonstrate its technique on rhesus macaque primates, in hope of bringing their treatment a step closer to human testing.